Found 36 articles
Bristol Myers Squibb Company forged an oncology drug discovery and development deal valued at more than $1 billion with Volastra Therapeutics.
Dewpoint Therapeutics Appoints Aravind Subramanian, Ph.D., as Head of Digital & Technology Platforms
Dewpoint Therapeutics today announced the appointment of Aravind Subramanian , Ph.D., as Head of Digital & Technology Platforms.
The funds raised will advance several of Dewpoint's programs to IND status with the FDA and enhance its multi-component biology platform and AI-driven data science platform.
Dewpoint Therapeutics, Inc., the biomolecular condensates company, announced the completion of a $150 million Series C financing.
Palantir Technologies Inc. and Dewpoint Therapeutics today announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases.
GRO Biosciences Announces Appointment of Bruce Beutel, PhD to Board of Directors and J.P. Morgan Health Care Conference Week Activities
GRO Biosciences Inc. today announced the appointment of Bruce Beutel, PhD to its Board of Directors and its upcoming participation and activity during J.P. Morgan Health Care Week in January 2022.
Today, Octant announced the appointment of Mark Murcko as Strategic Advisor and Board Member.
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Lori Escobedo as Chief People Officer.
PureTech Health plc announces its half-yearly results for the six months ended June 30, 2021.
Dewpoint Therapeutics today announced the appointment of Michael Wagner, Ph.D., as Senior Vice President of Chemistry and Drug Discovery.
Blackstone Life Sciences Expands Team of Biopharmaceutical, Medical Technology, and Diagnostics Experts with Appointments of Dr. Olivier Brandicourt, Dr. Omar Ishrak, Dr. Francois Nader, and Kim Popovits as Senior Advisors
Blackstone Life Sciences, the life sciences business of Blackstone (NYSE:BX), today announced the appointments of Dr. Olivier Brandicourt, former CEO of Sanofi, Dr. Omar Ishrak, former Chairman and CEO of Medtronic, Dr. Francois Nader, former CEO of NPS Pharma, and Kim Popovits, former CEO of Genomic Health, as Senior Advisors.
Dewpoint Therapeutics , the biomolecular condensates company, today announced the appointment of Isaac Klein, M.D., Ph.D., as Chief Scientific Officer, effective May 3, 2021 .
The New York-based company inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced its seed funding round was extended from $12 million to $44 million.
Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis
Company founded by Polaris Partners with latest financing led by Vida Ventures Funding will support advancement of novel approaches to predict and target metastasis, one of the biggest unsolved challenges in cancer
Volastra Therapeutics and Dewpoint Therapeutics Partner to Discover Novel Condensate Modulators for Cancer Treatment
Collaboration will combine Volastra's expertise in cancer biology with Dewpoint's platform for targeting condensates to identify drug candidates that can stop metastasis and disease progression
Dewpoint Therapeutics , the biomolecular condensates company, today announced that it has appointed Regina Barzilay , Ph.D., to its Board of Directors.
Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer and Treasurer.
Here’s a run-down of some of the most recent collaboration announcements this week.
Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy
Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.